It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...
Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...
The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...
In a case of consolidation in the Chinese pharma sector, LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million. Under the terms of the deal ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...
While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...
Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that includes an ...
The European Parliament has voted through reforms to legislation regulating the pharma sector, which the industry claims could compromise competitiveness and patient care. The new directive and ...
Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA, which called the drug a "significant ...
uniQure's gene therapy for Huntington's has hit the mark in a clinical trial, raising hopes of the first treatment for the devastating neurodegenerative disease. Shares in the biotech rose sharply ...
Navdeep "Navi" Chadha is co-founder and CTO of Axtria, a global provider of AI-powered data analytics and cloud software for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results